The Estée Lauder Companies announced on April 29 that it has made a minority investment in 111SKIN, a luxury clinical skincare brand. Financial terms of the deal were not disclosed.
Summary
- The Estée Lauder Companies takes a minority stake in luxury clinical skincare brand 111SKIN
- Founded by plastic surgeon Dr. Yannis Alexandrides, the brand is built on NAC Y2™ technology and a treatment-inspired approach
- Product range spans $50 to $1,000, with key collections including Black Diamond and Reparative
- Direct-to-consumer accounts for approximately 20% of sales, with North America representing around 40%
- Investment aligns with ELC’s strategy to expand in science-driven, high-performance skincare
- 111SKIN is expected to accelerate product innovation and global expansion
Founded in 2012 by Dr. Yannis Alexandrides, 111SKIN originated as a skincare solution developed to accelerate post-procedure healing for patients. The brand is rooted in clinical expertise, with formulations designed based on medical insights.
At the core of 111SKIN’s products is its proprietary complex NAC Y2™, developed to support skin repair and maintain a healthy, radiant complexion. Today, the brand offers more than 30 products and is positioned firmly within the luxury segment, with flagship collections such as Black Diamond and Reparative, priced between $50 and $1,000.
Commenting on the investment, Stéphane de La Faverie, President and CEO of The Estée Lauder Companies, stated: “Skin care is entering a new phase, shaped by the convergence of procedures, longevity and beauty, as consumers increasingly seek products that deliver visible, treatment-inspired results. 111SKIN exemplifies this shift, translating Dr. Alexandrides’ more than 35 years of surgical and aesthetic treatment experience into high-performance luxury skin care inspired by in-clinic treatments and built on clinical insight, next-generation actives, powerful formulas and proven efficacy. This investment, grounded in consumer-centricity and transformative innovation, reflects our Beauty Reimagined vision and underscores the significant opportunity we see to support the brand’s continued growth – expanding its global reach while preserving the distinctive approach that has made it so relevant with today’s consumers.”
Co-founder Dr. Yannis Alexandrides and Eva Alexandrides commented, “We are thrilled to be partnering with The Estée Lauder Companies and to unlock an exciting new chapter for 111SKIN.” CEO Vanessa Goddevrind also expressed confidence in the brand’s future trajectory. Dr. Alexandrides will remain actively involved and continue to lead the brand alongside its management team.
To date, 111SKIN has expanded across luxury retail, e-commerce, and high-end spa channels, including Harrods, Bluemercury, Nordstrom, Mandarin Oriental, and Aman.
Its direct-to-consumer business represents approximately 20% of total sales, highlighting strong engagement with prestige consumers. Regionally, North America accounts for around 40% of revenue as of 2025, alongside a growing presence in China, the United Kingdom, Europe, and Asia-Pacific.
This investment reflects The Estée Lauder Companies’ continued focus on science-driven innovation. As demand rises for clinical, high-performance skincare rooted in treatment concepts, the company is leveraging strategic investments to access high-growth segments. For 111SKIN, the partnership marks a key step toward advancing product development and expanding its global consumer reach.
Copyright © 2026 Oui Speak Fashion. All rights reserved.
Oui Speak Fashion (OSF)® is a New York-based Global Fashion, Beauty & Luxury Business Media Platform.